Ignite Creation Date:
2024-05-05 @ 12:09 PM
Last Modification Date:
2024-10-26 @ 9:21 AM
Study NCT ID:
NCT00267657
Status:
UNKNOWN
Last Update Posted:
2017-01-11
First Post:
2005-12-20
Brief Title:
A Phase 1 Parallel-Group Double-Blind Placebo-Controlled Cardiovascular and Behavioral Study Assessing Interactions Between Single Doses of Oral Reserpine and Intravenous Methamphetamine - 1
Sponsor:
National Institute on Drug Abuse NIDA
Organization:
National Institute on Drug Abuse NIDA
Study Overview
Official Title:
Assessment of Interactions Between IV Methamphetamine and Reserpine
Status:
UNKNOWN
Status Verified Date:
2005-12
Last Known Status:
ACTIVE_NOT_RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
In this parallel group clinical pharmacology laboratory experiment we will assess pharmacodynamic interactions with a focus on cardiovascular effects of a 15 mg intravenous methamphetamine dose and single oral doses of reserpine 05 and 10 mg or placebo
Detailed Description:
In this parallel group clinical pharmacology laboratory experiment we will assess pharmacodynamic interactions with a focus on cardiovascular effects of a 15 mg intravenous methamphetamine dose and single oral doses of reserpine 05 and 10 mg or placebo
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None